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Abstract 
A novel, sensitive and selective stability-indicating gradient reverse phase ultra 
performance liquid chromatographic method was developed and validated for 
the quantitative determination of desloratadine and sodium benzoate in 
pharmaceutical oral liquid formulation. The chromatographic separation was 
achieved on Acquity BEH C8 (100 mm x 2.1 mm) 1.7 µm column by using 
mobile phase containing a gradient mixture of solvent A (0.05 M KH2PO4 and 
0.07 M triethylamine, pH 3.0) and B (50:25:25 v/v/v mixture of acetonitrile, 
methanol and water) at flow rate of 0.4 mL/min. Column temperature was 
maintained at 40°C and detection was carried out at a wavelength of 272 nm. 
The described method shows excellent linearity over a range of 0.254 µg/mL to 
76.194 µg/mL for desloratadine and 1.006 µg/mL to 301.67 µg/mL for sodium 
benzoate. The correlation coefficient for desloratadine and sodium benzoate 
was more than 0.999. To establish stability-indicating capability of the method, 
drug product was subjected to the stress conditions of acid, base, oxidative, 
hydrolytic, thermal and photolytic degradation. The degradation products were 
well resolved from desloratadine and sodium benzoate. The developed method 
was validated as per international ICH guidelines with respect to specificity, 
linearity, LOD, LOQ, accuracy, precision and robustness.  154  N. Kumar et al.:   
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Introduction 
Desloratadine,  8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-
[1,2-b]pyridine (Fig. 1), is a peripheral histamine H1-receptor anatagonist commonly used 
to treat allergy symptoms such as nasal and nonnasal symptoms of seasonal allergic 
rhinits. Desloratadine is available as 5 mg tablets and 0.5 mg/mL syrup [1, 2]. Compared 
to tablet and capsule, liquid formulations favour a most rapid absorption of active 
substance. Liquid preparations are particularly susceptible to mocrobial growth because of 
the nature of their ingradtient. Such preparations require the presence of preservatives 
and antimicrobial agents to prevent chemical alteration and degradation of drug 
substance.  
Sodium benzoate, sodium salt of benzoic acid, is widely used as antimicrobial 
preservatives in cosmetics, foods and pharmaceutical products. Sodium benzoate used at 
a concentrataion of 0.02–0.5% in oral medicines, 0.5% in  parenteral  products and   
0.1–0.5% in cosmetics. Sodium benzoate (Fig. 1) has been used for the preservation of 
desloratadine syrup. The analysis of preservatives in commercial pharmaceutical products 
is particularly important for both quality assurance and consumer protection. International 
conference on harmonization and USFDA guidance recommends that the finished product 
shelf-life specification should also include identification test, preservative content and limits 
for antimicrobial preservative present [3, 4]. Therefore, the analysis of desloratadine into 
oral syrup in combination with preservative is required and essential. Some liquid 
chromatography (LC) methods are available for the determination of desloratadine in 
biological fluids [5–8]. Literature reported few RP-LC methods for the quantification 
desloratadine in pharmaceutical dosage forms [9–11]. Spectrofluorimetric method was 
also reported for the determination of desloratadine in dosage forms [12]. No 
pharmacopoeial monograph is available for desloratadine syrup. Several analytical 
procedures have been reported for the determination of sodium benzoate seperately or in 
combination with the other drugs by HPLC [13–19]. These methods may not be suitable 
for simultaneous determination of desloratadine and sodium benzoate together in one 
chromatographic run. 
To the best of our knowledge, there is no stability-indicating LC method reported for the 
simultaneous estimation of desloratadine and sodium benzoate in oral liquid formulation. 
Therefore, attempts were made in this study to develop a fast, sensitive, selective and 
stability-indicating reverse phase ultra-performance liquid chromatography (UPLC) method 
for the simultaneous determination of desloratadine and sodium benzoate in oral liquid 
formulation. The proposed method is able to seperate desloratadine and sodium benzoate 
with each other and from its impurities, degradation products and placebo components. 
The developed LC method was validated with respect to specificity, linearity, limit of 
detection and quantification, precision, accuracy and robustness. Force degradation 
studies were performed on the placebo and drug product. Developed method separates all 
degradation products from desloratadine and sodium benzoate and exhibits stability-  A Validated Stability-Indicating RP-UPLC Method for Simultaneous Determination of Desloratadine …155 
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indicating nature. These studies were  performed in accordance with established 
International Conference on Harmonization (ICH) guidelines.  
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Fig. 1.   Chemical structures of desloratadine and sodium benzoate. 
Results and Discussion 
Method Development and Optimization 
The main objective of the chromatographic method was to separate and quantitate 
desloratadine and sodium benzoate in presence of degradation products and other 
placebo components like flavor agents and colors. An isocratic method was employed 
using 0.05 M potassium dihydrogen ortho-phosphate (pH 3.5) and acetonitrile in the ratio 
of 75:25 as mobile phase, Acquity BEH C18 (100 mm x 2.1 mm) 1.7 µm column with flow 
rate of 0.4 mL/min on UPLC equipped with photo diode array detector. Sodium benzoate 
peak was eluted along with placebo peaks and base degradant eluted too late. To 
separate sodium benzoate from placebo peaks and reduce the run time an attempt was 
made with gradient elution with mobile phase 0.05 M potassium dihydrogen ortho-
phosphate buffer (pH 3.5) as solvent-A and solvent-B (mixture of acetonitrile and water in 
the ratio of 80:20 v/v). Sodium benzoate was resolved from placebo peaks but 
desloratadine peak eluted late along with degradation product. To resolve the 
desloratadine from degradation product and reduce the run time, pH of solvent A changed 
to 3.0 and solvent B modified to the mixture of acetonitrile, methanol and water in the ratio 
of 50:25:25 v/v/v, respectively and Acquity BEH C8 (100 mm x 2.1 mm) 1.7 µm column 
was selected for separation. On the optimization of gradient program, desloratadine and 
sodium benzoate peaks were well resolved from degradation products but peak tailing was 
observed more than 1.8. To reduce the peak tailing solvent-A was modified to 0.05 M 
KH2PO4  and 0.07 M triethylamine, adjusted pH to 3.0 with ortho-phosphoric acid and 
results to peak tailing less than 1.2. Based on these experiments, the final optimized 
conditions are described below. 
Acquity BEH C8 (100 mm x 2.1 mm) 1.7 µm was used as the stationary phase. The mobile 
phase A consisted of 0.05 M KH2PO4  and 0.07 M triethylamine, adjusted pH 3.0 with 
ortho-phosphoric acid and mobile phase B contained a mixture of acetonitrile, methanol 
and water in the ratio of 50:25:25 v/v/v, respectively. The flow rate was 0.4 mL/min with a 
gradient program of (time (min)/ %B) 0/27, 4.5/32.4, 5.2/80, 5.4/80, 5.5/27 and 7/27. The 
column temperature was maintained at 40°C and detection was monitored at 272 nm. The 
injection volume was 2 µL. The typical retention time of sodium benzoate and 
desloratadine was about 2.51 and 4.51 min, respectively.  156  N. Kumar et al.:   
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Validation of the Method  
The proposed method was validated by determining its performance characteristics 
regarding specificity, accuracy, precision, limit of detection and quantification, linearity, 
range and robustness [4, 20, 21]. 
System suitability 
System suitability shall be checked for the conformance of suitability and reproducibility of 
chromatographic system for analysis. System suitability was determined before sample 
analysis from five replicate injections of the standard solution containing 50 µg/mL of 
desloratadine and 200 µg/mL of sodium benzoate. The acceptance criteria were less than 
2% relative standard deviation (RSD) for peak areas, USP tailing factor less than 2.0 and 
USP plate count more than 5000 for desloratadine and sodium benzoate peaks from 
standard solution. All critical parameters tested met the acceptance criteria (Table 1). 
Tab. 1.  System suitability results  
Parameters  Acceptance  
criteria 
Desloratadine  Sodium benzoate 
Precision  Intermediate 
precision  Precision  Intermediate 
precision 
Area (%RSD, n=5)  ≤ 2.0  0.3  0.2  0.1  0.3 
USP Plate count  > 5000  18316  23951  13652  16936 
USP Tailing  ≤ 2.0  1.2  1.0  1.2  1.1 
 
Specificity 
Specificity is the ability of the method to measure the analyte response in the presence of 
its potential degradants and placebo matrix. In the present study, injections of blank and 
placebo were performed to demonstrate the interference with the elution of desloratadine 
and sodium benzoate. These results demonstrate that there was no interference at the 
retention time of desloratadine and sodium benzoate from the other compounds and, 
therefore, confirms the specificity of the method (Fig. 2).  
 
Fig. 2.   Overlay chromatogram of blank, placebo and sample.   A Validated Stability-Indicating RP-UPLC Method for Simultaneous Determination of Desloratadine …157 
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Forced degradation studies 
Force degradation studies of drug product were also performed to evaluate the stability-
indicating property and specificity of proposed method. Stress studies were performed at 
the concentration of 50 µg/mL of desloratadine and 200 µg/mL of sodium benzaoate on 
syrup formulation. Peak purity test was carried out for the desloratadine and sodium 
benzoate peaks by using PDA detector on stress samples. All the solutions used in forced 
degradation studies were prepared by dissolving the drug product in small volume of 
stressing agents. After degradation, these solutions were diluted with diluent to yield stated 
desloratadine and sodium benzoate concentration of about 50 µg/mL and 200 µg/mL, 
respectively. Conditions employed for performing the stress studies were as follows 
[4, 20, 21]: 
Acid induced degradation 
Acid hydrolysis was performed in 0.1 N HCl at 50°C for 20 hr but no degradation was 
observed. To achieve degradation, drug product was treated with 1 N HCl at 60°C for 20 
hr. Fig 3 shows major degradation peaks at RRT 0.30 and 0.34 with respect to 
desloratadine. All the major and minor degradation products were well separated from 
desloratadine and sodium benzoate peaks. The peak purity was checked for both analytes 
and the results are summarized in Table 2.  
Base induced degradation 
Base hydrolysis was carried out in 0.1 N NaOH at 50°C for 20 hr, but degradation of 
desloratadine was found to be less than 2% and sodium benzoate found stable. To 
increase the degradation, drug product was subjected to base hydrolysis in 1 N NaOH at 
60°C for 20 hr. Fig 4 shows that the major degradation peaks found at RRT 1.12 and 1.39 
with respect to desloratadine. All the major and minor degradation products were well 
separated from desloratadine and sodium benzoate peaks. The peak purity was checked 
for both analytes and the results are summarized in Table 2.  
Water induced degradation 
Water hydrolysis was performed in purified water at 60°C for 20 hr. Desloratadine and 
sodium benzoate were found stable under water hydrolysis stress conditions. The peak 
purity was checked for both analytes and the results are summarized in Table 2.  
Hydrogen peroxide induced degradation 
Oxidative degradation was performed in 1% hydrogen peroxide at 50°C for 20 hr but 
degradation of desloratadine and sodium benzoate were found to be less than 2% and 
0.4%, respectively. To achieve optimum degradation, drug product was treated with 6% 
hydrogen peroxide at 60°C for 20 hr. Fig 5 shows that the major degradation peaks found 
at RRT 0.30, 0.80 and 1.41 with respect to desloratadine. All the major and minor 
degradation products were well separated from desloratadine and sodium benzoate 
peaks. The peak purity was checked for both analytes and the results are summarized in 
Table 2. 
Heat induced degradation 
The drug product was exposed to dry heat at 105°C for 24 hr. Following removal from the 158  N. Kumar et al.:   
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oven, sample was prepared for analysis as previously described under sample 
preparation. Desloratadine and sodium benzoate were found stable under thermal stress 
conditions. The peak purity was checked for both analytes and the results are summarized 
in Table 2. 
Photo-degradation 
Photo degradation studies were carried out according to option 2 of ICH guideline Q1B 
[20]. Samples were exposed to white florescent light for an overall illumination of 1.2 
million lux hours and near UV radiation with an overall illumination of 200 watt/m
2/hr at 
25°C. Following removal from the photo-stability chamber, sample was prepared for 
analysis as previously described under sample preparation. No degradation was observed 
during photolytic degradation condition. The peak purity was checked for desloratadine 
and sodium benzoate and the results are summarized in Table 2. 
 
Fig. 3.   Typical chromatogram of acid degraded drug product 
 
Fig. 4.   Typical chromatogram of base degraded drug product   A Validated Stability-Indicating RP-UPLC Method for Simultaneous Determination of Desloratadine …159 
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Fig. 5.   Typical chromatogram of peroxide degraded drug product 
Tab. 2.  Summary of forced degradation results 
Stress Condition 
Desloratadine  Sodium benzoate 
% Degrad-
ation 
Purity  
angle 
Purity  
threshold 
% Degrad-
ation 
Purity  
angle 
Purity 
threshold 
Acid hydrolysis  
(1 N HCl at 60°C, 20 hr)  2.7  0.146  0.329  3.8  0.074  0.342 
Base hydrolysis 
(1 N NaOH at 60°C, 20 hr)  13.8  0.064  0.287  0.0  0.075  0.356 
Oxidation 
(6% H2O2 at 60°C, 20 hr)  13.3  0.068  0.257  1.6  0.102  0.334 
Thermal 
(At 105°C, 24 hr)  0.5  0.059  0.250  0.0  0.060  0.330 
Hydrolytic 
(Water at 60°C, 20 hr)  1.5  0.074  0.250  0.0  0.070  0.345 
Photolytic  
(1.2 million lux hr visible 
light and 200 wh/m
2 UV 
light) 
0.0  0.089  0.253  0.0  0.057  0.324 
 
Limits of Detection (LOD) and Quantification (LOQ)  
The LOD and LOQ were determined at a signal-to-noise ratio of 3:1 and 10:1, respectively, 
by injecting a series of dilute solutions with known concentrations. The limit of detection 
and limit of quantification values of desloratadine and sodium benzoate are reported in 
Table 3. 
Linearity  
Linearity test solutions were prepared at seven concentrations ranging from LOQ to 150% 
levels of test concentration (LOQ – 76.2 µg/mL for desloratadine and LOQ – 150.8 µg/mL 
for sodium benzoate). The peak area was plotted against the concentration at each level 
and a calibration curve was generated by least-squares linear regression analysis. The 160  N. Kumar et al.:   
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coefficient correlation, slope, y-intercept of the calibration curve and % bias at 100% 
response are reported (Table 3) and results show that an excellent correlation existed 
between peak area and concentration of desloratadine and sodium benzoate. 
Tab. 3.  Evaluation of LOD, LOQ and linearity data 
Parameter  Desloratadine  Sodium benzoate 
LOD (µg/mL)  0.086  0.342 
LOQ (µg/mL)  0.254  1.006 
Linearity range (µg/mL)  0.254–76.194  1.006–301.670 
Correlation coefficient  0.9998  0.9999 
Intercept (a)  −936.968  123.469 
Slope (b)  7370.222  1732.966 
Bias at 100% response  −0.03  0.00 
 
Precision  
The precision of method was verified by repeatability and intermediate precision. 
Repeatability was checked by injecting six individual preparations of desloratadine syrup 
containing desloratadine and sodium benzoate at 10%, 50%, 100% and 150% level of test 
concentration (5.1, 25.4, 50.8, and 76.2 µg/mL for desloratadine; and 20.1, 100.6, 201.1 
and 301.7 µg/mL for sodium benzoate). The intermediate precision of the method was also 
evaluated using different analyst and different instrument and performing the analysis on 
different days. Intermediate precision was determined by injecting six individual 
preparations of desloratadine syrup containing desloratadine and sodium benzoate at 
10%, 50%, 100% and 150% level of test concentration (5.1, 25.4, 50.8, and 76.2 µg/mL for 
desloratadine; and 20.1, 100.6, 201.1 and 301.7 µg/mL for sodium benzoate). The relative 
standard deviation of the areas of each peak was calculated and found to less than 0.9% 
in repeatability and less than 1.3% in intermediate precision, which confirms the good 
precision of the method. The %RSD values are presented in Table 4. 
Tab. 4.  Precision results determined during method validation 
Parameter  Spiked 
level 
% RSD (n=6) 
Desloratadine  Sodium benzoate 
Repeatability 
10%  0.9  0.2 
50%  0.7  0.1 
100%  0.2  0.1 
150%  0.5  0.2 
Intermediate Precision 
10%  0.5  0.6 
50%  1.2  1.3 
100%  0.5  0.4 
150%  0.3  0.3 
 
Accuracy  
Accuracy of the method for desloratadine and sodium benzoate was evaluated in triplicate 
at 10%, 50%, 100% and 150% level of test concentration (5.1, 25.4, 50.8, and 76.2 µg/mL   A Validated Stability-Indicating RP-UPLC Method for Simultaneous Determination of Desloratadine …161 
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for desloratadine; and 20.1, 100.6, 201.1 and 301.7 µg/mL for sodium benzoate). The 
percentage recoveries for both components were calculated (Table 5). The percentage 
mean recovery of desloratadine and sodium benzoate from the formulation varied from 
98.9 to 102.0% indicating that the developed method was accurate for the determination of 
desloratadine and sodium benzoate in pharmaceutical formulation.  
Tab. 5.  Accuracy results  
Spiked level    Desloratadine  Sodium benzoate 
10%  % Recovery  101.1  102.0 
% RSD  0.5  0.2 
50%  % Recovery  100.7  100.5 
% RSD  1.0  0.1 
100%  % Recovery  99.9  100.8 
% RSD  0.2  0.1 
150%  % Recovery  98.9  99.7 
% RSD  0.7  0.1 
Mean % recovery and %RSD for three determinations. 
 
Robustness  
The robustness of the method was evaluated during development by making small, but 
deliberate, changes to the method parameters. The variables evaluated in the study were 
pH of the mobile phase buffer (±  0.2), column temperature (±  5°C), flow rate (±  0.04 
mL/min) and % organic in the mobile phase (± 10%) and system suitability parameters 
such as % RSD, retention time, tailing factor and theoretical plates of desloratadine and 
sodium benzoate standard were studied. In all the deliberate varied chromatographic 
conditions, system suitability parameters met the acceptance criteria (Table 6). Thus, the 
method was found to be robust with respect to variability in applied conditions.  
Stability of analytical solutions  
The solution stability of desloratadine and sodium benzoate in the assay method was 
investigated by leaving standard and sample solutions in tightly capped volumetric flask at 
room temperature for 48 hr. The same sample solutions were analyzed at the end of the 
study period against freshly prepared standard solutions. The variability in the assay of 
both substances was within ± 3% during solution stability. The results from solution 
stability experiments confirmed that sample solution and standard solutions were stable up 
to 48 hr.  
Experimental 
Reagents and chemicals 
Standard and syrup of desloratadine was supplied by Dr. Reddy’s laboratories limited, 
Hyderabad, India. Sodium benzoate was procured from United States Pharmacopoeia 
(USP). The HPLC grade acetonitrile and methanol; and analytical grade potassium di-
hydrogen ortho-phosphate, trietylamine and ortho-phosphoric acid were purchased from 162  N. Kumar et al.:   
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Merck, Mumbai, India. High purity water was prepared by using Millipore Milli-Q Plus water 
purification system (Millipore, Milford, MA, USA).  
Tab. 6.  Robustness results of UPLC method 
Variation in 
chromatographic 
condition 
Observed system suitability parameters 
Sodium Benzoate  Desloratadine 
tR
a  A
b  T
c  N
d  tR
a  A
b  T
c  N
d 
Column 
Temperature 35°C  2.920  0.2  1.1  16726  4.311  0.4  1.1  23937 
Column 
Temperature 45°C  2.581  0.1  1.1  16456  4.220  0.2  1.1  24810 
Flow rate  
0.36 mL/min  3.053  0.1  1.1  16463  4.676  0.3  1.1  25236 
Flow rate  
0.44 mL/min  2.493  0.2  1.1  13913  3.929  0.3  1.1  20747 
Acetonitrile 90%  2.856  0.0  1.2  10864  4.580  0.1  1.1  9559 
Acetonitrile 110%  2.632  0.1  1.2  8645  3.960  0.1  1.1  11869 
Methanol 90%  2.722  0.0  1.2  14235  4.148  0.1  1.1  20175 
Methanol 110%  2.734  0.1  1.4  9104  4.308  0.1  1.3  10681 
Mobile Phase 
Buffer pH 2.8  2.801  0.5  1.1  16206  3.404  0.1  1.1  19877 
Mobile Phase 
Buffer pH 3.2  2.668  0.1  1.3  9748  4.827  0.1  1.2  15093 
a Retention time (min) of the analyte peak. 
b % RSD of the analyte peak areas from 5 injections. 
c Tailing factor of the analyte peak. 
d Plate count of the analyte peak. 
 
Equipment 
The chromatography analysis was performed using Waters Acquity
TM UPLC separation 
module (Waters Corporation, Milford, USA) equipped with PDA detector, binary solvent 
manager and auto sampler system. The output signals were monitored and processed 
using Empower 2 software. Cintex digital water bath was used for hydrolysis studies. 
Photo-stability studies were carried out in photo-stability chamber (Sanyo, Leicestershire, 
UK). Thermal stability studies were performed in a dry air oven (Cintex, Mumbai, India). 
The pH of the solutions was measured by a pH meter (Mettler-Toledo, Switzerland). 
Chromatographic Conditions 
The separation was achieved on Acquity BEH C8 (100 mm x 2.1 mm) 1.7 µm column with 
mobile phase containing a gradient mixture of solvent A (0.05 M potassium dihydrogen 
ortho-phosphate and 0.07 M trietylamine, pH adjusted to 3.0 with ortho-phosphoric acid) 
and B (50:25:25 v/v/v mixture of acetonitrile, methanol and water) at a flow rate of 0.4 
mL/min. The gradient program (Time(min)/%B) was set 0/27, 4.5/32.4, 5.2/80, 5.4/80, 
5.5/27 and 7/27. The column oven temperature was maintained at 40°C and eluted 
compounds were monitored at the wavelength of 272 nm. The sample injection volume 
was 2 µL. 
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Preparation of Standard Solution 
Buffer (0.05 M KH2PO4, pH 3.0) and methanol in the ratio of 50:50 v/v was used as diluent. 
The stock solutions of desloratadine (0.25 mg/mL) and sodium benzoate (0.5 mg/mL) were 
prepared by dissolving an appropriate amount of analyte in diluent, separately. Working 
standard solution was prepared in diluent  from mixing above stock solutions of 
desloratadine and sodium benzoate with final concentration of 50 µg/mL and 200 µg/mL, 
respectively. 
Preparation of Sample Solution 
An amount (about 6 gm) of oral solution equivalent to 2.5 mg desloratadine was 
transferred into 50 mL volumetric flask, added 35 mL of diluent and ultrasonicated for 15 
min, and then diluted to volume with diluent to give a solution containing 50 µg/mL of 
desloratadine and 200 µg/mL of sodium benzoate.  
Conclusion 
A simple and efficient reversed-phase  UPLC method was developed and validated for 
quantitative analysis of desloratadine and sodium benzoate in pharmaceutical dosage 
forms. The method was found to be precise, accurate, linear, robust and rugged during 
validation. Satisfactory results were obtained from the validation of the method. The 
method is stability-indicating and can be used for routine analysis of production samples 
and to check the stability of the desloratadine syrup.  
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